As psychiatry struggles to develop new, more effective treatments, clinical trials combining psychotherapy and the drug MDMA, also known as Ecstasy, are producing stunning results. New research suggests that incorporating psychedelics like MDMA and psilocybin into talk therapy can dramatically boost outcomes with an array of issues, including PTSD, anxiety, depression, relationship blocks, even drug addiction. If ongoing trials continue with favorable results, FDA approval for certified therapists to use MDMA- and psilocybin-assisted therapy in their practices could be on the horizon. Guided in this workshop by the psychiatrist at the helm of the MDMA-assisted psychotherapy trials, you’ll explore:
- The rationale for using drugs like MDMA, psilocybin and other psychedelics as catalysts for psychotherapy
- The MDMA-assisted psychotherapy process, illustrated with video clips
- How these inner-directed approaches to therapy respect and support clients’ innate healing intelligence
- New opportunities for psychotherapists to receive training in this approach
Michael Mithoefer, MD, is a psychiatrist who conducted the first FDA-approved clinical trials of MDMA-assisted psychotherapy for PTSD. He trains and supervises therapists involved in the final phase of this research.